Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 3/20 | 0.43 |
| ▸ | FPR1 | P21462 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 8/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891655 | 0.80 | TSHR (0.47) | TSHRCYP17A1F10ALDH1A1 | |
| SCHEMBL28753705 | 0.79 | NPC1 (0.44) | TSHRCYP17A1FPR2FPR1F10 | |
| SCHEMBL5440338 | 0.78 | F10 (0.58) | FPR2FPR1F10HDAC6HDAC1 | |
| SCHEMBL8514563 | 0.78 | FPR2 (0.64) | FPR2FPR1HDAC6HDAC1HDAC8 | |
| SCHEMBL16468268 | 0.77 | FPR2 (0.67) | FPR2FPR1HDAC6HDAC1HDAC8 | |
| SCHEMBL5219240 | 0.77 | FPR2 (0.64) | FPR2FPR1HDAC6HDAC1HDAC8 | |
| SCHEMBL19471942 | 0.76 | HDAC1 (0.61) | FPR2FPR1HDAC6HDAC1HDAC8 | |
| SCHEMBL19471943 | 0.76 | HDAC1 (0.61) | FPR2FPR1HDAC6HDAC1HDAC8 | |
| SCHEMBL5185610 | 0.76 | F10 (0.42) | FPR2FPR1F10HDAC6HDAC1 | |
| SCHEMBL14372323 | 0.75 | TSHR (0.50) | TSHRCYP17A1F10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059726-A1 | Pyrrolidine-2-ones as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059726-A1 | Pyrrolidine-2-ones as factor xa inhibitors | TFPI, F2, SERPINC1 | TSHR 2187/4885CYP17A1 1651/4885FPR2 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.